Sugi Predict

Sugi Predict / Compounds / SCHEMBL4434657

SCHEMBL4434657

SCHEMBL4434657

O=C(CNS(=O)(=O)c1ccc(N2CCC(c3ccccc3)CC2)cc1)NO

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MMP2 P08253 7/20 0.56
▸ MMP13 P45452 6/20 0.56
▸ MEP1B Q16820 6/20 0.56
▸ MMP1 P03956 5/20 0.56
▸ MMP14 P50281 5/20 0.56
▸ MMP9 P14780 4/20 0.56
▸ MMP3 P08254 4/20 0.56
▸ ADAM17 P78536 3/20 0.56
▸ MMP7 P09237 1/20 0.56
▸ MMP8 P22894 1/20 0.56
▸ MMP12 P39900 1/20 0.56
▸ ADAMTS4 O75173 3/20 0.53
▸ ADAMTS5 Q9UNA0 3/20 0.53
▸ NPC1 O15118 1/20 0.47
▸ SMN1; SMN2 Q16637 2/20 0.46
▸ MEN1 O00255 1/20 0.46
▸ LMNA P02545 1/20 0.46
▸ GAA P10253 1/20 0.46
▸ HBB P68871 1/20 0.46
▸ KMT2A Q03164 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4426623 0.90 MMP3 (0.54) MMP2MMP13MMP1MMP9MMP3
SCHEMBL7468288 0.84 MMP3 (0.47) MMP2MMP13MEP1BMMP1MMP14
SCHEMBL6417993 0.83 MMP3 (0.52) MMP2MMP13MMP9MMP3NPC1
SCHEMBL7574729 0.76 MMP2 (0.52) MMP2MMP13MMP9MMP3NPC1
SCHEMBL4431389 0.76 MMP3 (0.70) MMP2MMP13MMP1MMP9MMP3
SCHEMBL4431378 0.76 MMP3 (0.70) MMP2MMP13MMP1MMP9MMP3
SCHEMBL6419780 0.76 MMP3 (0.67) MMP2MMP13MMP1MMP9MMP3
SCHEMBL6419785 0.76 MMP3 (0.67) MMP2MMP13MMP1MMP9MMP3
SCHEMBL6418278 0.76 MMP3 (0.70) MMP2MMP13MMP1MMP9MMP3
SCHEMBL2553981 0.75 MEP1B (0.81) MMP2MMP13MEP1BMMP1MMP14

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0874836-B1 SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES WARNER LAMBERT CO (US) 2002-10-09 — — EP claimed
US-5977141-A Sulfonamide inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 1999-11-02 — — US claimed
EP-0874836-A1 SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1998-11-04 — — EP claimed
WO-1997019068-A1 SULFONAMIDE INHIBITORS OF MATRIX METALLOPROTEINASES WARNER-LAMBERT COMPANY (US) 1997-05-29 — — WO claimed
US-20090186834-A1 DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS MICROBIA, INC. (US) 2009-07-23 — — US disclosed
US-20090005321-A1 Phenylazetidinone Derivatives MICROBIA, INC. (US) 2009-01-01 — — US disclosed
US-20080194494-A1 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia MICROBIA, INC. (US) 2008-08-14 — — US disclosed
WO-2008039829-A2 DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS IRONWOOD PHARMACEUTICALS, INC. (US) 2008-04-03 — — WO disclosed
WO-2006102674-A2 DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS MICROBIA, INC. (US) 2006-09-28 — — WO disclosed
US-20050020607-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2005-01-27 — — US disclosed
US-20040176393-A1 Statin-MMP inhibitor combinations NEWTON ROGER SCHOFIELD (US) 2004-09-09 — — US disclosed
EP-1366765-A1 Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing WARNER-LAMBERT COMPANY LLC (US) 2003-12-03 — — EP disclosed
EP-1028716-A1 METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION WARNER-LAMBERT COMPANY (US) 2000-08-23 — — EP disclosed
WO-2000004892-A2 COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS WARNER-LAMBERT COMPANY (US) 2000-02-03 — — WO disclosed
US-5977141-A Sulfonamide inhibitors of matrix metalloproteinases WARNER-LAMBERT COMPANY (US) 1999-11-02 — — US disclosed
EP-0946166-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1999-10-06 — — EP disclosed
WO-1999047138-A1 STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-09-23 — — WO disclosed
WO-1999032150-A1 ACE INHIBITOR-MMP INHIBITOR COMBINATIONS WARNER-LAMBERT COMPANY (US) 1999-07-01 — — WO disclosed
WO-1998026773-A1 USE OF MATRIX METALLOPROTEINASE INHIBITORS FOR TREATING NEUROLOGICAL DISORDERS AND PROMOTING WOUND HEALING WARNER-LAMBERT COMPANY (US) 1998-06-25 — — WO disclosed
WO-1998025597-A2 METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION WARNER-LAMBERT COMPANY (US) 1998-06-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080194494-A1 4-Biarylyl-1-Phenylazetidin-2-One Glucuronide Derivatives for Hypercholesterolemia CYP46A1, CYP7A1, UGT1A1 MMP2 1658/4885MMP13 3376/4885MEP1B 3080/4885
US-20040176393-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 MMP2 19/4885MMP13 13/4885MEP1B 2040/4885
US-20050020607-A1 Statin-MMP inhibitor combinations MMP9, TIMP3, MMP3 MMP2 19/4885MMP13 13/4885MEP1B 2040/4885
US-20090186834-A1 DIPHENYLHETEROCYCLE CHOLESTEROL ABSORPTION INHIBITORS NPC1L1, CYP46A1, NPC1 MMP2 2127/4885MMP13 4390/4885MEP1B 1243/4885
US-20090005321-A1 Phenylazetidinone Derivatives TYR, AAAS, FANCD2 MMP2 2619/4885MMP13 4166/4885MEP1B 1390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.